Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Biohaven Ltd. and SK Biopharmaceuticals Sign Strategic Licensing Agreement for Opakalim in Epilepsy

Aug 26, 2026•about 6 hours ago

Contract Type

agreement

United StatesBiotechnologyHealth CareTherapeutics

Description

Biohaven Ltd. and SK Biopharmaceuticals have entered into a strategic global licensing agreement for Biohaven's Kv7 ion channel platform and lead candidate Opakalim. SK Biopharmaceuticals will provide up to $795 million in upfront and milestone payments along with tiered royalties based on U.S. net sales.

Company Information

Company

Biohaven Ltd

Location

United States

About

Biohaven Ltd. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological and neuropsychiatric diseases. The company's key products primarily include treatments that address disorders such as migraine and other central nervous system conditions. Operating from its headquarters in New Haven, Connecticut, Biohaven serves markets primarily in the United States and has established a presence in the New York Stock Exchange under the ticker symbol BHVN. As an emerging growth company, Biohaven is dedicated to innovation in drug development and aims to enhance patient outcomes through research and strategic partnerships.

Related People

Suggested for you
Vlad
Likely contact at this company
••••••••@••••••••

See Vlad's verified email →

Bruce
Senior decision-maker at this company
••••••••@••••••••

See Bruce's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Biohaven Ltd's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Biohaven Ltd signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.